BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mediwatch: Placing Raises 347,000


11/9/2009 2:44:58 PM

Mediwatch plc (AIM: MDW, “Mediwatch” or the “Company”), the innovative urological diagnostic company, has raised 347,440 (approximately 332,000 net of expenses) by way of a cash placing of 6,042,430 new ordinary shares ("Placing Shares") at 5.75 pence per share (together the "Placing").

Use of funds

Proceeds from the Placing will be used to fund working capital and to finance four feasibility studies for new opportunities which Mediwatch has identified to support its international growth plans. These are:

1. To work with an international corporation on a joint venture, sharing technology and pursuing a common marketing campaign.

2. A project with a different international medical company, assessing the potential of using its technology with Mediwatch’s bioassays.

3. A marketing opportunity with a biomedical company to promote its point-of-care system alongside the Mediwatch PSA system for assessment of urological problems.

4. Licensing a bladder cancer marker from a different bioscience company and to conduct a research project using that marker with the Mediwatch BioScan reader system.

The Placing Shares have been subscribed for by certain institutional shareholders of the Company and by all Directors of the Company. The Directors have subscribed for a total of 501,000 Placing Shares.

The Placing Shares will represent 4.32 per cent of the issued ordinary share capital of the Company as enlarged by the Placing and the total number of voting shares in issue immediately following admission to trading on AIM will be 139,713,502.

Application will be made to the London Stock Exchange plc for the Placing Shares to be admitted to trading on AIM and it is expected that admission will take place on 13 November 2009. The Placing Shares will rank pari passu in all respects with the Company's existing ordinary shares of 1p each.

Philip Stimpson, Mediwatch Chief Executive said: “We have identified four opportunities, each of which - if successful - will enable us to extend our range of offerings in the international urology market in different ways. While we are unable to provide details at this stage, each is exciting in its own right and will help us to achieve our aim of providing a “one-stop” system of urological diagnostic equipment for the international healthcare market.”


Read at BioSpace.com

Mediwatch
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES